Login to Your Account

Adolor Falls On Contradictory Pivotal Entereg Data For OB

By Karen Pihl-Carey

Wednesday, September 6, 2006
Adolor Corp. lost almost half its value Tuesday after reporting results from three trials evaluating Entereg (alvimopan) for opioid-induced bowel dysfunction. Two of the trials failed to meet the primary endpoint, including one study designed to support a new drug application filing in the middle of 2007. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription